This Plain Language Summary of Publication from Future Rare Diseases describes the results from two ongoing study which looks at two approved treatments for a rare blood disease called nocturnal hemoglobinuria (PNH). The two treatments which under investigation in this study are called Eculizumab and ravulizumab. This article describes the results at 2 years for both studies.

Read the full article here.

This Plain Language Summary of Publication from Future Rare Diseases describes the results from two ongoing study which looks at two approved treatments for a rare blood disease called nocturnal hemoglobinuria (PNH). The two treatments which under investigation in this study are called Eculizumab and ravulizumab. This article describes the results at 2 years for both studies.

The original article on which this Plain Language Summary of Publication is based is titled ‘Long-term safety and efficacy of ravulizumab in patients withparoxysmal nocturnal hemoglobinuria: 2-year results from twopivotal phase 3 studies’ and was published in the European Journal of Haematology. Read the original article here.